Trial Profile
A Phase II Randomized, Open Label, Immunogenicity and Safety Trial of the Vaccine Based on the Recombinant Biologically Active HIV-1 Tat Protein in Anti-Tat Negative HIV-1 Infected HAART-Treated Adult Subjects.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs HIV vaccine (Primary)
- Indications HIV-1 infections
- Focus Pharmacodynamics
- 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 20 Jul 2011 Primary endpoints, antibody levels, CD4+ and CD8+ cell count levels, were met according to results presented at the 6th International AIDS Society Conference on HIV Pathogenesis and Treatment.